Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
OBJECTIVE
The aims of this study were to determine the response rate of pyrazoloacridine (PZA) in patients with recurrent or persistent endometrial carcinoma and to describe the nature and degree of toxicity in this population.


METHODS
PZA was initially administered at a dose of 750 mg/m(2) intravenously over 3 h every 3 weeks but, due to toxicity, was subsequently reduced to 560 mg/m(2) at the same schedule.


RESULTS
Among 23 evaluable patients, 11 of whom had had prior chemotherapy, there was 1 (4.3%) partial response and no complete responses. Forty-eight percent of patients had grade 4 neutropenia. There was 1 treatment-related death, in a patient who had prior chemotherapy and radiotherapy.


CONCLUSIONS
This dose and schedule of PZA has insignificant activity in this population. The optimal PZA dose appears to vary between different populations and may be related to prior therapy.
Plaxe
Steven C
SC
Division of Gynecologic Oncology, University of California at San Diego, San Diego, California 92103, USA.
Blessing
John A
JA
Husseinzadeh
Nader
N
Webster
Kenneth D
KD
Rader
Janet S
JS
Dunton
Charles J
CJ
D000166:Acridines / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*
D000166:Acridines; D000970:Antineoplastic Agents; D011720:Pyrazoles; C064541:NSC 366140